Bjt-778

5 trials 2 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

1 Sponsors

11 Countries

Phase III

Phase II/III

Phase I/II

Phase III: 2 Phase II/III: 2 Phase I/II: 1

Indications tested

Hepatitis D 5 Chronic hepatitis B 1

Sponsors using this IMP

Bluejay Therapeutics Inc. 5

All trials

5 total

Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting

2025-522015-42-00 Phase II/III 7 countries Bluejay Therapeutics Inc.
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta I… Recruiting

2024-517167-23-00 Phase III 8 countries Bluejay Therapeutics Inc.
Phase 3 Study to Evaluate Brelovitug vs Delayed Treatment for Treatment of Chronic Hepatitis Delta Infection (AZURE-4) Ended

2025-522105-38-00 Phase III 3 countries Bluejay Therapeutics Inc.
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatit… Ended

2024-519063-18-00 Phase II/III 1 country Bluejay Therapeutics Inc.
A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778… Expired

2022-502724-46-00 Phase I/II 3 countries Bluejay Therapeutics Inc.

Showing 1–5 of 5 trials

← All drugs A–Z